Sucampo shares slide after its lead experimental drug flunks a PhIIa test


Shares of Sucampo Pharmaceuticals ($SCMP) slumped Tuesday morning after the biotech reported that its lead experimental drug flubbed a Phase IIa trial, forcing investigators to shutter the program.

Sucampo’s stock was down about 20% in premarket trading as investors reacted to the news that cobiprostone failed to meaningfully improve heartburn symptoms for proton pump inhibitor-resistant non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD).

But the drug--a chloride channel activator--isn’t dead.


Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

“While these data did not support the advancement of cobiprostone in this indication, the data did demonstrate that cobiprostone was well-tolerated, and this is consistent with our earlier Phase I studies,” said Rockville, MD-based Sucampo CSO Peter Kiener in a statement. “We plan to continue our development of cobiprostone in our ongoing Phase IIa study for the prevention of oral mucositis--a disorder with very different underlying pathophysiology and clinical endpoints. This development plan includes a futility analysis on the ongoing trial in the second half of this year.”

Sucampo has been developing a market for its constipation drug Amitiza. Jason Gerberry at Leerink recently estimated 2019 sales of that drug at $500 million, adding that the cobiprostone study was probably its most important pipeline catalyst this year.


Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.